Back to School: How biopharma can reboot drug development. Access exclusive analysis here

DNA repair technology regulatory update

OXGN received U.S. Patent No. 6,020,351 covering

Read the full 72 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE